HAS THE NEW ANTIDIABETIC DRUG, N1-SULPHANILYL-N2-N-BUTYLCARBAMIDE GOITROGENIC PROPERTIES?

Abstract
The new anti-diabetic drug, N1-sulphanilyl-N2-n-butylcarbamide, was somewhat goitrogenic in the rat at a daily oral dose of 0.5 g/kg of body weight. The thyroids not only increased in weight but appeared to be histologically more active. The serum protein-bound iodine was lower in the experimental animals than in the controls.

This publication has 2 references indexed in Scilit: